NSCLC Treatment
- introduction of NSCLC Treatment
- Pathologic stage I to IIIA (N1) of NSCLC Treatment
- Pathologic stage IIIA (N2) to IIIB disease of NSCLC Treatment
- Adeno or Other in Stage IV NSCLC Treatment (裡面有重要的 → 表格！)
- Squam
- PD-L1 ≥50%: Pembrolizumab or chemo/pembro (NEJM 2016;375:1823)
- PD-L1 <50%: Chemo [carbo/paclitaxel] + pembro (NEJM 2018;379:2040)
參考 ➡️ Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Many are specific tyrosine kinase inhibitors (‘tinibs) directed against EGFR, ALK, etc. Amivantamab is → an EGFR- MET bispecific mAb. Pembrolizumab is → a mAb against PD-1 on lymphocytes (ie, an immune checkpoint inhibitor).